Korean J Gastroenterol.  2021 Jul;78(1):69-71. 10.4166/kjg.2021.093.

Risk of Hepatocellular Carcinoma in Patients with Non-alcoholic Fatty Liver Disease

• Kim DY
• Park JY

• KMID: 2518760
• DOI: http://doi.org/10.4166/kjg.2021.093

Abstract

Non-invasive Stratification of Hepatocellular Carcinoma Risk in Non-alcoholic Fatty Liver Using Polygenic Risk Scores

Reference

1. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. 2019; From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 16:411–428. DOI: 10.1038/s41575-019-0145-7. PMID: 31028350.

2. Eslam M, Newsome PN, Sarin SK, et al. 2020; A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 73:202–209. DOI: 10.1016/j.jhep.2020.03.039. PMID: 32278004.

3. Loomba R, Lim JK, Patton H, El-Serag HB. 2020; AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology. 158:1822–1830. DOI: 10.1053/j.gastro.2019.12.053. PMID: 32006545. PMCID: PMC8012107.

4. Bianco C, Jamialahmadi O, Pelusi S, et al. 2021; Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 74:775–782. DOI: 10.1016/j.jhep.2020.11.024. PMID: 33248170. PMCID: PMC7987554.

5. Eslam M, Valenti L, Romeo S. 2018; Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 68:268–279. DOI: 10.1016/j.jhep.2017.09.003. PMID: 29122391.

6. Kim DY, Park JY. 2020; Genetic risk factors associated with NAFLD. Hepatoma Res. 6:85. DOI: 10.20517/2394-5079.2020.96.

7. Younossi ZM. 2017; Long-term outcomes of nonalcoholic fatty liver disease: from nonalcoholic steatohepatitis to nonalcoholic steatofibrosis. Clin Gastroenterol Hepatol. 15:1144–1147. DOI: 10.1016/j.cgh.2017.05.029. PMID: 28549675.

8. Estes C, Anstee QM, Arias-Loste MT, et al. 2018; Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 69:896–904. DOI: 10.1016/j.jhep.2018.05.036. PMID: 29886156.

9. Torkamani A, Wineinger NE, Topol EJ. 2018; The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 19:581–590. DOI: 10.1038/s41576-018-0018-x. PMID: 29789686.

10. Khera AV, Chaffin M, Aragam KG, et al. 2018; Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 50:1219–1224. DOI: 10.1038/s41588-018-0183-z. PMID: 30104762. PMCID: PMC6128408.